Finally, a positive outcome may fuel initiatives to study the ability of GLP-1 agonists to prevent the development of the pre-diabetes, for example, by starting treatment shortly after treatment with SGAs are initiated in high-risk patients. The gene discussed is GCG; the disease is diabetes mellitus.